Amit Nathwani

Amit Nathwani is a highly experienced individual who currently serves as the Founder and CEO of NovalGen. Amit also holds the position of Professor of Haematology at UCL. Notably, Amit has been involved in groundbreaking AAV gene therapy developments for haemophilia B in collaboration with St. Jude Children's Research Hospital. Amit's contributions have paved the way for effective gene therapy treatments for haemophilia A and have been licensed to companies like UniQure Therapeutics and BioMarin. In addition, Amit Nathwani is a founding member and Chief Scientific Officer of Freeline Therapeutics.